pirarubicin

Phase 2Small molecule

PPeking University People's Hospital

pirarubicin is one of 73 small molecule programs targeting Osteosarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteosarcomaRecruiting

TreatmentRecruiting

OsteosarcomaPhase 2

Recruiting

TreatmentPhase 1

Recruiting

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Dexilant

Takeda

Preclinical

2 2

Theo-Dur

Pfizer

Preclinical

1 3

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 4

Valium

Akero Therapeutics

Preclinical

2 5

pirarubicin

PPeking University People's Hospital

Phase 2

1 6

Lotemax

PPharmos

Preclinical

1 7

Norpramin

VValidus Pharmaceuticals

Preclinical

1 8

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 9

Clomid

Ferring

Preclinical

1 10

Crixivan

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ANot yet recruiting

Breast Cancer

NCT05287308

Q3 2030

Phase 1Recruiting

Treatment

NCT07178171

Q2 2045

Post-ApprovalNot yet recruiting

Combination Therapy

NCT03892330

Clinical

Trials by Indication[1]

Urothelial Carcinoma3 trials

Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients

Unknown status·PPeking University First Hospital·Phase 2·NCT02740426·200 enrolled

Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients

Unknown status·PPeking University First Hospital·Phase 2·NCT02923557·200 enrolled

Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma

Unknown status·RRenJi Hospital·Phase 2·NCT03030157·220 enrolled

Breast Cancer2 trials

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

Completed·—·Phase 3·NCT02613026·104 enrolled

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Not yet recruiting·CChinese Academy of Medical Sciences·N/A·NCT05287308·500 enrolled

Metastatic Soft-tissue Sarcoma1 trial

Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma

Withdrawn·PPeking University People's Hospital·Phase 2/3·NCT03342300

Combination Therapy1 trial

Combination Therapy of Anthracyclines for Children With Nephroblastoma

Not yet recruiting·SShengjing Hospital·Phase 4·NCT03892330·120 enrolled

Acute Lymphoblastic Leukemia1 trial

Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJapan Adult Leukemia Study Group·Phase 2·NCT00131053·120 enrolled

3 more indications

Hepatocellular Carcinoma1 trial

Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma

Withdrawn·GGuangxi Medical University·Phase 2/3·NCT02585479

Osteosarcoma1 trial

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Recruiting·PPeking University People's Hospital·Phase 2·NCT06714383·50 enrolled

Treatment1 trial

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Recruiting·XXijing Hospital·Phase 1·NCT07178171·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for pirarubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pirarubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pirarubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking University People's Hospital

pirarubicin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2030

Q2 2045

Trials by Indication[1]

Urothelial Carcinoma3 trials

Breast Cancer2 trials

Metastatic Soft-tissue Sarcoma1 trial

Combination Therapy1 trial

Acute Lymphoblastic Leukemia1 trial

Hepatocellular Carcinoma1 trial

Osteosarcoma1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News